<HTML><HEAD></HEAD><BODY>Erbitux: Japanese approval highlights a growing trend for personalized therapy | TradingMarkets.com  New ETF Book by Larry Connors Click here to read more
</br>
 Erbitux: Japanese approval highlights a growing trend for personalized therapy
</br>
Posted on: Tue, 30 Mar 2010 05:59:47 EDT
</br>
, ,  Do you know when to trade  &  ?Check for a  from TradingMarkets  Mar 30, 2010 Datamonitor via COMTEX In a move that mirrors earlier FDA and EMA decisions, the PMDA in Japan has granted additional approval for the use of Erbitux in combination with first line chemotherapy for the treatment of colorectal cancer.The decision is likely to strengthen Erbitux's position in Japan, giving it an edge over rival Avastin, and marks another step in the growing trend toward personalized therapy in oncology.The Japanese Pharmaceutical and Medical Devices Agency PMDA has granted approval to Erbitux cetuximab; Eli Lilly/Merck Serono/Bristol Myers Squibb in combination with chemotherapy for the first line treatment of unresectable,<b><font color='green'> advanced</font></b> or recurrent colorectal cancer patients with wild type KRAS tumors.This extended use approval follows a product label change for Erbitux, as a result of the submission of additional clinical trial data from the Phase III CRYSTAL study to the PMDA.The CRYSTAL study randomized 1,198 metastatic colorectal cancer patients to receive standard first line FOLFIRI 5 fluorouracil, leucovorin and irinotecan chemotherapy with or without Erbitux.Initial results showed that the benefits of adding Erbitux to chemotherapy are greater in wild type KRAS patients, while those with mutant KRAS derive no benefit at all.Updated results presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium in January 2010 showed that the addition of Erbitux offers a statistically significant overall survival benefit for wild type KRAS patients.Wild type KRAS patients in the Erbitux arm showed overall survival of 23.5 months compared to 20.0 months in those receiving chemotherapy alone.In addition, the combination of Erbitux and chemotherapy significantly reduced the risk of disease progression by 30%, and increased tumor response from 40% to 57%.In the US and Europe, Erbitux's label was changed to reflect the KRAS data in 2009 and 2008, respectively.The PMDA's decision to change Erbitux's label in Japan adds further impetus to the growing trend in oncology towards personalized medicine.Given that two thirds of colorectal cancer patients carry the wild type KRAS gene, demand for Erbitux will continue to rise.This is especially significant in Japan, which has the highest incidence rate of colorectal cancer on a global scale.This is likely due to the traditional diet in this area, which is high in salts, nitrates and smoked or pickled foods, a known risk factor for gastrointestinal cancers.An established screening program for colorectal cancer exists in Japan, which is another contributor to the high incidence seen here.If a personalized regimen proves more effective in treating metastatic colorectal cancer, it will further strengthen Erbitux's position in this market and give it an edge over rival Avastin bevacizumab; Genentech/Roche .http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent.Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon For full details on Bristol Myers Squibb Co BMY .Bristol Myers Squibb Co BMY has Short Term PowerRatings at TradingMarkets.Details on Bristol Myers Squibb Co BMY Short Term PowerRatings is available at For full details on Merck & Co MRK .Merck & Co MRK has Short Term PowerRatings at TradingMarkets.Details on Merck & Co MRK Short Term PowerRatings is available at For full details on Eli Lilly & Company LLY .Eli Lilly & Company LLY has Short Term PowerRatings at TradingMarkets.Details on Eli Lilly & Company LLY Short Term PowerRatings is available at Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day.Join us for our  20 minute tele seminars during the week.Thursday April 29 12:30 PM Hear What Kevin Haggerty Sees in the Stock Market Today!Wednesday April 28 01:00 PM Hear What Gary Kaltbaum Sees in the Stock Market Today!* Attendance is strictly limited and are filled on a first come, first served basis. </br>
</BODY></HTML>